Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M878Revenue (TTM) $M--Net Margin (%)--Altman Z-Score
Enterprise Value $M18.5EPS (TTM) $--Operating Margin %--Piotroski F-Score--
P/E(ttm)--Beneish M-Score--Pre-tax Margin (%)--Higher ROA y-yN
Price/Book4.710-y EBITDA Growth Rate %--Quick Ratio--Cash flow > EarningsN
Price/Sales--5-y EBITDA Growth Rate %--Current Ratio--Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)--Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)--Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M8,800,002ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with FBT

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
(Average)*
Current Price Change from Average Comment Current Shares

FBT is held by these investors:



FBT: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Rapps, MichaelDirector, Director or Senior Officer of 10% Securi 2017-01-16Buy1,200$9.48959.92view
Gridley, Anthony RonaldSenior Officer 2017-01-16Sell1,800$16.94493.15view
DINWOODIE, TYLER WAYNE PAULSenior Officer 2017-01-16Buy4,000$0.1759005.88view
Brown, Mark ThomasDirector 2017-01-16Sell29,300$1.367288.24view
Bebek, IvanDirector 2017-01-16Buy8,990$3.382872.78view
smith, laurie james10% Security Holder, Director, Senior Officer 2017-01-16Buy7,500$0.4124407.32view
MEHR, JEFFREYSenior Officer 2017-01-13Sell50,000$27.91260.01view
Squibb, Geoffrey WayneDirector 2017-01-13Buy267$6.271502.55view
Smith, DavidSenior Officer 2017-01-13Sell15,000$60.3866.41view
Rowlands, William BruceDirector, Senior Officer 2017-01-13Buy20,000$0.1566886.67view

Quarterly/Annual Reports about FBT:

    News about FBT:

    Articles On GuruFocus.com
    No related article found.

    More From Other Websites
    Biotech ETFs Powered by Q4 Earnings Feb 10 2017
    Politics Plague Biotech ETFs Feb 01 2017
    What Lies Ahead for Biotech ETFs in Trump Era? Jan 27 2017
    Here's How to Play the Biotech Rebound Jan 25 2017
    United Therapeutics: Will RemoSynch Become a Key Growth Driver? Dec 29 2016
    How Could Gilead Sciences Restore Its Growth? Dec 01 2016
    Why Neurocrine Biosciences May See Higher Losses in 2016 Dec 01 2016
    5 Reasons to Buy 5 Low P/E Biotech ETFs Nov 14 2016
    What Drove Regeneron’s 3Q16 Performance? Nov 09 2016
    Biotech ETFs Slumping on Q3 Results Nov 08 2016
    Strensiq: A Potential Driver for Alexion Nov 02 2016
    Once Beloved Momentum ETF Loses Its Momo Oct 27 2016
    Exclusive: SunTrust Managing Director Shares Thoughts On Drug Pricing, Impact On Biotech Oct 20 2016
    What Are the Drivers behind the Success of Soliris? Oct 20 2016

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)